Latest From EnGeneIC Ltd.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.
AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
- Antisense, Oligonucleotides
- Drug Delivery
- Therapeutic Areas
- Parent & Subsidiaries
- EnGeneIC Ltd.
- Senior Management
Jennifer MacDiarmid, PhD, Joint CEO
Bill Harris, CFO
David Seaton, COO
Scott Pattison, VP, Clinical Operations
- Contact Info
Phone: 2 9420 5844
2/25 Sirius Rd.
Lane Cove West
New South Wales, 2066
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.